As of 2025-05-23, the Intrinsic Value of Taro Pharmaceutical Industries Ltd (TARO) is 39.63 USD. This TARO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 42.97 USD, the upside of Taro Pharmaceutical Industries Ltd is -7.80%.
The range of the Intrinsic Value is 29.98 - 70.78 USD
Based on its market price of 42.97 USD and our intrinsic valuation, Taro Pharmaceutical Industries Ltd (TARO) is overvalued by 7.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 29.98 - 70.78 | 39.63 | -7.8% |
| DCF (Growth 10y) | 38.60 - 94.03 | 51.77 | 20.5% |
| DCF (EBITDA 5y) | 37.65 - 59.57 | 44.06 | 2.5% |
| DCF (EBITDA 10y) | 42.90 - 69.18 | 50.84 | 18.3% |
| Fair Value | 7.16 - 7.16 | 7.16 | -83.35% |
| P/E | 21.07 - 44.28 | 35.44 | -17.5% |
| EV/EBITDA | 23.57 - 52.01 | 35.64 | -17.1% |
| EPV | 19.01 - 21.43 | 20.22 | -52.9% |
| DDM - Stable | 10.73 - 36.97 | 23.85 | -44.5% |
| DDM - Multi | 23.27 - 65.77 | 34.79 | -19.0% |
| Market Cap (mil) | 1,614.81 |
| Beta | 0.81 |
| Outstanding shares (mil) | 37.58 |
| Enterprise Value (mil) | 1,192.96 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.41% |
| Cost of Debt | 5.00% |
| WACC | 6.57% |